Evidence map›Paper›PMID 23242192›Full record

Trial reportEuropean heart journal2013

A randomized study of remote follow-up of implantable cardioverter defibrillators: safety and efficacy report of the ECOST trial.

Laurence Guédon-Moreau, Dominique Lacroix, Nicolas Sadoul, Jacques Clémenty, Claude Kouakam, Jean-Sylvain Hermida, Etienne Aliot, Michel Boursier, Olivier Bizeau, Salem Kacet and 1 more

2 registry-linked trialsOpen access · bronzeAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in European heart journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 120 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed, 8 pooled it
13.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00989417 nacompletednot on this map

Effectiveness and Cost Of ICD Follow-up Schedule With Telecardiology

TypeinterventionalSponsorBiotronik SE & Co. KGRan2007 to 2010Enrolled473ConditionsImplantable Cardioverter-Defibrillators, Ventricular Fibrillation, Tachycardia, VentricularArmsACTIVATION of HOME MONITORING
NCT02989090 nacompletednot on this mapstarted 2014, after this paper: background citation

Electronic Patient Notification of Remote Implantable Cardioverter-Defibrillator (ICD) Monitoring Data: Impact of Patient Engagement on Outcomes in the Merlin.Net™ System

TypeinterventionalSponsorParkview Hospital, IndianaRan2014 to 2015Enrolled191ConditionsImplantable Cardioverter-Defibrillator, Health Information Exchange, Electronic Health Records, Patient ParticipationArmsReceive Detailed ICD Information-electronic, Receive Detailed ICD Information-paper
3 · Its place in the literature

Who cites it

120 citing papers in PubMed, 8 syntheses or guidelines pooled it, 312 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Knowledge Update on the Economic Evaluation of Pacemaker Telemonitoring Systems.International journal of environmental research and public health · 2021
    Pooled it
  5. Inappropriate shocks in single-chamber and subcutaneous implantable cardioverter-defibrillators: a systematic review and meta-analysis.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2017
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Cost-consequence analysis of daily continuous remote monitoring of implantable cardiac defibrillator and resynchronization devices in the UK.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2013
    Pooled it
  9. Trial
  10. Trial
  11. Effect of remote monitoring on clinical outcomes in European heart failure patients with an implantable cardioverter-defibrillator: secondary results of the REMOTE-CIED randomized trial.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2022
    Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. REmote SUpervision to Decrease HospitaLization RaTe. Unified and integrated platform for data collected from devices manufactured by different companies: Design and rationale of the RESULT study.Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc · 2017
    Trial

60 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Laurence Guédon-MoreauCentre Hospitalier Régional et Universitaire, Lille, France. laurence.guedon@chru-lille.fr
Dominique Lacroix
Nicolas Sadoul
Jacques Clémenty
Claude Kouakam
Jean-Sylvain Hermida
Etienne Aliot
Michel Boursier
Olivier Bizeau
Salem Kacet
ECOST trial Investigators
Centre Hospitalier Universitaire de Lille · FRCentre Hospitalier Régional et Universitaire de Nancy · FRBon Secours Hospital · USCentre hospitalier régional d'Orléans · FRCentre Hospitalier Universitaire Amiens-Picardie · FRHôpital Cardiologique du Haut-Lévêque · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThe ECOST trial examined prospectively the long-term safety and effectiveness of home monitoring (HM) of implantable cardioverter defibrillators (ICD). METHODS AND

resultsThe trial's primary objective was to randomly compare the proportions of patients experiencing ≥ 1 major adverse event (MAE), including deaths from all causes, and cardiovascular, procedure-related, and device-related MAE associated with HM (active group) vs. ambulatory follow-ups (control group) in a sample of 433 patients. The 221 patients assigned to the active group were seen once a year, unless HM reported an ICD dysfunction or a clinical event requiring an ambulatory visit, while the 212 patients in the control group underwent ambulatory visits every 6 months. The characteristics of the study groups were similar. Over a follow-up of 24.2 months, 38.5% of patients in the active and 41.5% in the control group experienced ≥ 1 MAE (P < 0.05 for non-inferiority). The overall number of shocks delivered was significantly lower in the active (n = 193) than in the control (n = 657) group (P < 0.05) and the proportion of patients who received inappropriate shocks was 52% lower in the active (n = 11) than in the control (n = 22) group (P < 0.05). At the end of the follow-up, the battery longevity was longer in the active group because of a lower number of capacitor charges (499 vs. 2081).

conclusionOur observations indicate that long-term HM of ICD is at least as safe as standard ambulatory follow-ups with respect to a broad spectrum of MAE. It also lowered significantly the number of appropriate and inappropriate shocks delivered, and spared the device battery. Clinical trials registration NCT00989417.

Indexed as

Ambulatory CareArrhythmias, CardiacCause of DeathDefibrillators, ImplantableFemaleFollow-Up StudiesHumansMaleMiddle AgedMonitoring, AmbulatoryProspective StudiesRemote ConsultationTreatment Outcome

Identifiers

PMID23242192
PMCPMC3578267
OpenAlexW2131839079

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.